Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARTISTRY-2: Nemvaleukin Alfa Monotherapy and with Pembrolizumab in Advanced Solid Tumors
NCT03861793Phase 2Completed
- Sponsor
- Mural Oncology
- Start
- Feb 2019
- Primary completion
- Mar 2023
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 6
01
Overview
Phase 2, open-label trial of nemvaleukin alfa in solid tumor, gastric cancer (GC), ovarian cancer and 2 more (2 arms), sponsored by Mural Oncology. Primary endpoints: Incidence of Adverse Events up to 24 months, Recommended Phase 2 Dose up to 24 months and 2 more. Started Feb 2019; status: completed.
02
Drugs
nemvaleukin alfa
03
Conditions
solid tumorgastric cancer (GC)ovarian cancernon-small cell lung cancer (NSCLC)squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT03861793.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03861793.